Close

BofA/Merrill Lynch Upgrades Qiagen NV (QGEN) to Neutral

Go back to BofA/Merrill Lynch Upgrades Qiagen NV (QGEN) to Neutral

QIAGEN Reports Results for Third Quarter and First Nine Months of 2016

November 2, 2016 4:03 PM EDT

VENLO, the Netherlands, November 2, 2016 /PRNewswire/ --

QIAGEN records strong third quarter with accelerating 2016 performance:  Q3 2016: Net sales of $338.7 million (+8% actual, +9% constant exchange rates, CER); EPS of $0.14; adjusted EPS of $0.29 ($0.29 CER)  Free cash flow in first nine months of 2016 up 15% to $187 million   Molecular Diagnostics and Life Sciences customer classes deliver strong performance as Sample to Insight... More